Literature DB >> 16940442

Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist.

Stephanie T Page1, John K Amory, Bradley D Anawalt, Michael S Irwig, Andrew T Brockenbrough, Alvin M Matsumoto, William J Bremner.   

Abstract

INTRODUCTION: Exogenous androgens plus progestins can be used to suppress spermatogenesis, resulting in effective male hormonal contraception; however, induction of azoospermia can require 3-6 months, and these methods require injectable or implantable androgens. We hypothesized that testosterone (T) transdermal gel (T gel) could be combined with a depot formulation of the progestin, depomedroxyprogesterone acetate (DMPA), with or without the potent GnRH antagonist, acyline, to suppress spermatogenesis conveniently, rapidly, and reversibly.
OBJECTIVES: The objectives of the study were: 1) to determine the rate of severe oligospermia (< or = 1 million sperm/ml) using T gel+DMPA; and 2) to determine whether the addition of acyline to T gel+DMPA during the first 12 wk of the regimen would accelerate and improve suppression of spermatogenesis.
METHODS: Forty-four healthy men, ages 18-55 yr, were randomized to T gel (100 mg daily)+DMPA (300 mg/3 months) or acyline (300 microg/kg.2 wk x 12 wk)+T gel+DMPA. Thirty-eight men completed the 24-wk treatment protocol.
RESULTS: All men had dramatic suppression of spermatogenesis; 90% of the subjects became severely oligospermic, a rate comparable to implantable and injectable T+progestin combinations. The addition of acyline did not significantly accelerate spermatogenic suppression or improve rates of severe oligospermia. There were no serious adverse events, and there were minimal changes in weight, serum lipids, and prostate-specific antigen.
CONCLUSIONS: The combination of T gel+DMPA is a promising new regimen in male contraception. The addition of the GnRH antagonist acyline, as part of an induction phase in a male contraception regimen, has limited clinical utility. Additional studies using T gel for male contraception are warranted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16940442     DOI: 10.1210/jc.2006-1411

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  24 in total

1.  Characteristics associated with suppression of spermatogenesis in a male hormonal contraceptive trial using testosterone and Nestorone(®) gels.

Authors:  M Y Roth; N Ilani; C Wang; S T Page; W J Bremner; R S Swerdloff; C Dart; R Sitruk-Ware; N Kumar; D Blithe; J K Amory
Journal:  Andrology       Date:  2013-09-30       Impact factor: 3.842

Review 2.  Injection of testosterone may be safer and more effective than transdermal administration for combating loss of muscle and bone in older men.

Authors:  Stephen E Borst; Joshua F Yarrow
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-04-21       Impact factor: 4.310

3.  An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer.

Authors:  Laurent Boccon-Gibod; Egbert van der Meulen; Bo-Eric Persson
Journal:  Ther Adv Urol       Date:  2011-06

Review 4.  Pipeline for contraceptive development.

Authors:  Diana L Blithe
Journal:  Fertil Steril       Date:  2016-08-11       Impact factor: 7.329

Review 5.  Progress and prospects in male hormonal contraception.

Authors:  John K Amory
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2008-06       Impact factor: 3.243

Review 6.  Advances in male contraception.

Authors:  Stephanie T Page; John K Amory; William J Bremner
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

Review 7.  Beyond the Condom: Frontiers in Male Contraception.

Authors:  Mara Y Roth; John K Amory
Journal:  Semin Reprod Med       Date:  2016-03-04       Impact factor: 1.303

8.  Oral administration of the GnRH antagonist acyline, in a GIPET-enhanced tablet form, acutely suppresses serum testosterone in normal men: single-dose pharmacokinetics and pharmacodynamics.

Authors:  John Kenneth Amory; Thomas W Leonard; Stephanie T Page; Edel O'Toole; Michael J McKenna; William J Bremner
Journal:  Cancer Chemother Pharmacol       Date:  2009-05-29       Impact factor: 3.333

9.  Combined transdermal testosterone gel and the progestin nestorone suppresses serum gonadotropins in men.

Authors:  Vahid Mahabadi; John K Amory; Ronald S Swerdloff; William J Bremner; Stephanie T Page; Regine Sitruk-Ware; Peter D Christensen; Narender Kumar; Yun-Yen Tsong; Diana Blithe; Christina Wang
Journal:  J Clin Endocrinol Metab       Date:  2009-04-14       Impact factor: 5.958

10.  Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis.

Authors:  Peter Y Liu; Ronald S Swerdloff; Bradley D Anawalt; Richard A Anderson; William J Bremner; Joerg Elliesen; Yi-Qun Gu; Wendy M Kersemaekers; Robert I McLachlan; M Cristina Meriggiola; Eberhard Nieschlag; Regine Sitruk-Ware; Kirsten Vogelsong; Xing-Hai Wang; Frederick C W Wu; Michael Zitzmann; David J Handelsman; Christina Wang
Journal:  J Clin Endocrinol Metab       Date:  2008-02-26       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.